"Ezetimibe" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An azetidine derivative and ANTICHOLESTEREMIC AGENT that inhibits intestinal STEROL absorption. It is used to reduce total CHOLESTEROL; LDL CHOLESTEROL, and APOLIPOPROTEINS B in the treatment of HYPERLIPIDEMIAS.
Descriptor ID |
D000069438
|
MeSH Number(s) |
D03.383.082.301.550
|
Concept/Terms |
Ezetimibe- Ezetimibe
- (1-(4-fluorophenyl)-(3R)-(3-(4-fluorophenyl)-(3S)-hydroxypropyl)-(4S)-(4-hydroxyphenyl)-2-azetidinone)
- Ezetimib
SCH 58235- SCH 58235
- 58235, SCH
- SCH-58235
- SCH58235
|
Below are MeSH descriptors whose meaning is more general than "Ezetimibe".
Below are MeSH descriptors whose meaning is more specific than "Ezetimibe".
This graph shows the total number of publications written about "Ezetimibe" by people in this website by year, and whether "Ezetimibe" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2002 | 0 | 2 | 2 |
2003 | 0 | 3 | 3 |
2004 | 0 | 2 | 2 |
2005 | 0 | 2 | 2 |
2006 | 0 | 2 | 2 |
2008 | 0 | 3 | 3 |
2009 | 0 | 2 | 2 |
2011 | 0 | 3 | 3 |
2012 | 0 | 2 | 2 |
2013 | 0 | 2 | 2 |
2015 | 2 | 1 | 3 |
2016 | 0 | 1 | 1 |
2017 | 1 | 0 | 1 |
2018 | 0 | 1 | 1 |
2019 | 1 | 0 | 1 |
2021 | 0 | 1 | 1 |
2023 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ezetimibe" by people in Profiles.
-
Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments. Curr Atheroscler Rep. 2024 02; 26(2):35-44.
-
Aggressive LDL-C Lowering and the Brain: Impact on Risk for Dementia and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2023 10; 43(10):e404-e442.
-
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial. J Clin Lipidol. 2023 Jul-Aug; 17(4):491-503.
-
Association between ezetimibe usage and hepatitis C RNA levels in uninfected kidney transplant recipients who received hepatitis C infected kidneys. Clin Transplant. 2021 12; 35(12):e14485.
-
Usefulness of Gemcabene in Homozygous Familial Hypercholesterolemia (from COBALT-1). Am J Cardiol. 2019 12 15; 124(12):1876-1880.
-
Comparing remnant lipoprotein cholesterol measurement methods to evaluate efficacy of ezetimibe/statin vs statin therapy. J Clin Lipidol. 2019 Nov - Dec; 13(6):997-1007.e8.
-
Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials. J Am Heart Assoc. 2018 09 18; 7(18):e009221.
-
The natural history of phytosterolemia: Observations on its homeostasis. Atherosclerosis. 2018 02; 269:122-128.
-
Effect of ezetimibe on plasma adipokines: a systematic review and meta-analysis. Br J Clin Pharmacol. 2017 07; 83(7):1380-1396.
-
Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control. Circulation. 2016 Dec 13; 134(24):1931-1943.